CD20

31개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved31 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyCurated CoreFDAstaleRocheApproved

rituximab (Rituxan)

US label: non-Hodgkin lymphoma, CLL, rheumatoid arthritis, GPA/MPA and pemphigus vulgaris; population-specific indicati… · CD20

#CD20#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 1337Status Approved
AntibodyCurated CoreFDAstaleRocheApproved

glofitamab (Columvi, RO7082859, glofitamab-gxbm)

Relapsed or refractory diffuse large B-cell lymphoma · CD20 × CD3

#CD20CD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 90Status Approved
AntibodyCurated CoreFDAstaleGenmabApproved

epcoritamab (Epkinly, GEN3013, Tepkinly, epcoritamab-bysp)

Relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma · CD20 × CD3

#CD20CD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 57Status Approved
AntibodyLimited DatastaleRochePhase 3

Ocrelizumab, Rituximab, Ofatumumab (Anti-CD20 therapies, Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab))

Relapsing-Remitting Multiple Sclerosis (RRMS); Anti-CD20 Therapy · CD20

#CD20#Antibody#Phase3#monoclonal-antibody#Relapsing-RemittingMultipleScler+3
Trials 40Status Recruiting
AntibodyLimited DatastaleKyverna TherapeuticsPhase 2

Anti-CD20 mAB (Anti-CD20 mAB)

Multiple Sclerosis, Primary Progressive; Multiple Sclerosis, Secondary Progressive · CD20

#CD20#Antibody#Phase2#monoclonal-antibody#MultipleSclerosis+3
Trials 31Status Recruiting
CGTLimited DatastalePersonGen BioTherapeutics (Suzh…Phase 1

CD19/CD20 CAR-T cell infusion (CD19/CD20 CAR-T cell infusion)

CAR · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 30Status Active
CGTLimited DatastaleHebei Senlang Biotechnology Inc…Phase 1

Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells (Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells)

19 and 22+ B Cell Hematologic Tumors; 19 and 20+ B Cell Hematologic Tumors · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 8Status Recruiting
CGTLimited DatastaleChinese PLA General HospitalPhase 2

anti-CD20-CAR vector-transduced autologous T cells (anti-CD20-CAR vector-transduced autologous T cells)

Hematopoietic/Lymphoid Cancer; Adult Acute Lymphoblastic Leukemia in Remission · CD20

#CD20#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 5Status Active
CGTLimited DatastaleBeijing BiotechPhase 1

CD20/BCMA-directed CAR-T cells (CD20/BCMA-directed CAR-T cells)

Systemic Lupus Erythematosus (SLE); Immune-mediated Necrotizing Myopathy (IMNM) · CD20

#CD20#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 3Status Recruiting
AntibodyLimited DatastaleRochePhase 2

rituximab (Anti-CD20, Anti-CD20 (rituximab))

Presymptomatic Diabetes Type 1 (Stage 1); Diabetes Mellitus, Type I · CD20

#CD20#Antibody#Phase2#monoclonal-antibody#PresymptomaticDiabetesType1Stage+3
Trials 2Status Active
CGTLimited DatastaleOhio State University Comprehen…Phase 1

Autologous Anti-CD19/CD20/CD22 CAR T-cells (Autologous Anti-CD19/CD20/CD22 CAR T-cells)

Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive; Recurrent Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 2Status Recruiting
CGTLimited DatastaleChina Immunotech Pharmaceutical…Phase 1

CD19/CD20 Dual-CAR-T cells (CD19/CD20 Dual-CAR-T cells)

B-cell Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 2Status Active
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-CD19 and anti-CD20 bicistronic CAR T- cells (Anti-CD19 and anti-CD20 bicistronic CAR T- cells)

Chronic Lymphocytic Leukemia; B-Cell Chronic Lymphocytic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleSumithira VasuPhase 1

Anti-CD19/CD20/CD22 CAR T-Cells (Anti-CD19/CD20/CD22 CAR T-Cells)

Recurrent Acute Lymphoblastic Leukemia; Recurrent B Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleSouthwest Hospital, ChinaPhase 2

Anti-CD20-CAR-transduced T cells (Anti-CD20-CAR-transduced T cells)

Leukemia; Lymphoma · CD20

#CD20#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD19/CD20 dual-target CAR-T module (Autologous CD19/CD20 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleSouthwest Hospital, ChinaPhase 2

CD19 or CD20 CAR T cells briging HSCT (CD19 or CD20 CAR T cells briging HSCT)

Lymphoma, Large B-Cell, Diffuse; Leukemia, Lymphocytic, Chronic, B-Cell · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastaleHenan Hualong Biotechnology Com…Phase 1

CD19/CD20 bispecific CAR-T cells (CD19/CD20 bispecific CAR-T cells)

B-Cell Lymphoma Stage I; Refractory · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastalePeking UniversityPhase 1

CD19/CD20-directed Chimeric Antigen Receptor T Cells (CD19/CD20-directed Chimeric Antigen Receptor T Cells)

B Cell Non-Hodgkin's Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleShanghai Cell Therapy Group Co.…Phase 1

CD19/CD20/BCMA CAR T cells (CD19/CD20/BCMA CAR T cells)

Non-Hodgkin Lymphoma, B-cell · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting

1 / 2 pages

← PreviousNext →